Temporal Lobe Epilepsy: Cell Death and Molecular Targets by Maria José da Silva Fernandes et al.
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1. Introduction 
According to data from the World Health Organization (WHO), epilepsy is a common 
chronic brain disorder affecting approximately 50 million people worldwide. The hallmark 
of epilepsy is the recurrence of seizures, which on a cellular level is characterized by 
synchronized discharges of large groups of neurons that interrupt normal function. TLE is 
the most frequent type of human epilepsy (Engel, 2001; Willianson et al., 1993). In about 40% 
of patients, the seizures are refractory to medical therapy (De Lanerolle & Lee, 2005). The 
majority of these patients suffer from symptomatic focal epilepsies, which are frequently a 
consequence of brain trauma, complicated febrile convulsions, prolonged seizures (status 
epilepticus; SE), ischemic lesions and brain tumors (French et al., 1993; Mathern et al., 1995).  
Neuroimaging and cognitive testing of patients with refractory epilepsy also suggest 
detrimental effects as a result of repeated seizures over time, including volume reduction 
within the involved brain structures. TLE syndrome is characterized by partial seizures that 
may or may not be secondarily generalized. The common symptoms include abdominal 
sensations and fear in patients with mesial temporal sclerosis (Devinski, 2004).  
Neuropathological studies indicate that TLE is frequently associated with hippocampal 
sclerosis that is routinely detected by imaging studies during the presurgical evaluation of 
patients with an intractable TLE (Mathern et al., 1995). In a review, de Lenarolle and Lee 
(2005) cited that about 70% of hippocampi removed surgically from patients with TLE 
showed hippocampal sclerosis, and 30% did not show sclerosis, known as paradoxical TLE. 
The etiology and the pathogenesis of this type of medial temporal lobe damage are not 
known. Several studies have shown a correlation between severe childhood illness 
(infection, febrile convulsions, prolonged seizure and hippocampal atrophy in TLE 
(Cavanagh & Meyer 1956; Mathern et al., 1995). However, not all TLE patients exhibiting 
hippocampal damage have a history of an initial insult. Some experimental and human data 
suggest that recurrent seizures may cause progressive damage to the hippocampus 
(Sloviter, 1983; Mathern et al., 1995). Until recently, it was unknown whether the damage 
found in the hippocampus was the cause or the consequence of TLE. However, the surgical 
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removal of the sclerotic hippocampus results in the best seizure-free outcome (De Lanerolle 
& Lee, 2005).  
2. Neuropathological findings in temporal lobe epilepsy 
The hippocampus or Ammon’s horn is one of the most vulnerable areas in the temporal lobe 
to develop cell loss following seizures. The histological pattern of hippocampal sclerosis in 
TLE patients is characterized by the loss of pyramidal cells in the prosubiculum and the 
CA1 of the hippocampus (Mathern et al., 1995). These findings also include neuronal loss in 
the hilus of the dentate gyrus and the adjacent CA3 region of the hippocampus (Mouritzen, 
1982; Babb & Lieb 1984). In many cases, the hippocampal damage in TLE was accompanied 
by aberrant mossy fiber reorganization. Mossy fibers from the dentate granule cells, which 
normally innervate the hilar mossy cells and the CA3 pyramidal cells and interneurons, 
reorganize and project into the inner third of the molecular layer of the dentate gyrus 
(Sutula et al., 1989; Babb et al., 1991; Szabadics & Soltesz, 2009). The term "mesial temporal 
sclerosis" has been introduced to describe cellular damage in the hippocampus, amygdala 
and entorhinal cortex (De Lanerolle & Lee, 2005). 
3. Epileptogenesis 
The development of an epileptic disorder involves a cascade of events that become activated 
by an initial insult to the brain. Based on studies using animal models (Turski et al., 1983; 
Leite et al., 1990) or human patients, there is a period so that events triggered by an initial 
insult (trauma or SE) can generate an active epileptic focus. It is believed that this latency 
period (weeks in animal models or years in patients) reflects a reaction mechanism resulting 
from cellular loss and is required for the synaptic reorganization to occur, which leads to an 
increased excitability and to changes in synchronization that establishes the chronic 
epileptic disorder. Figure 1 is a schematic diagram showing the events activated at different 
time points following an insult in human and in animal epilepsy models, which could be 
involved with the development of spontaneous seizures.  
Thus, epilepsy can be considered an active process that results in both ictal phenomena and 
permanent interictal functional and structural changes in the brain (Mathern et al., 1995). 
Patients who develop TLE demonstrate a progression in both the number of seizures and in 
the neurological symptoms related to the seizure, such as cognitive and behavioral disorders 
(Engel et al., 1991, French et al., 2004). The long latency before the usual complex partial 
seizures form in TLE offers a potential time window for therapeutic interventions, which 
may be a good alternative to prevent the appearance of seizures. 
4. Experimental animal models of TLE  
The experimental animal models provide a useful approach to assess the mechanisms 
involved in the epileptogenesis. The damage precedes the appearance of spontaneous 
seizures in several animal models of partial epilepsies. SE induced by systemic injection of 
pilocarpine or kainic acid caused structural brain damage in rats. Cell loss was observed in 
the hilus and the CA3 region of the hippocampus as well as in the amygdala, entorhinal 
cortex, thalamus and cerebral cortex (Turski et al., 1983). Moreover, prominent mossy fiber 
sprouting occurred (Mello et al., 1993). According to Olney et al. (1974), kainic acid and 
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Fig. 1. A schematic diagram of epileptogenesis in patients and an experimental model of 
TLE. An initial precipitant insult can cause lesioning or functional changes. During a latent 
period, which can take years (5-10 years) in patients or weeks (2-3 weeks) in animal models, 
the insult initiates the reorganization of the brain and becomes prone to generate 
spontaneous motor seizures. Epileptogenesis includes changes that involve cell death, 
inflammation, neurogenesis, gliosis, sprouting, dendritic plasticity, and blood-brain barrier 
damage (Pitkanen & Lukasiuk, 2011). The short time frame for the development of the main 
features of the pathogenesis of TLE in animals encourages use in this study.  
other glutamate analogues are toxic because they activate glutamate receptors on neuronal 
membranes, resulting in prolonged depolarization, neuronal swelling and death. By 
activating M1 muscarinic receptors, pilocarpine activates phospholipase C, which in turn 
produces diacylglycerol (DG) and inositol triphosphate (IP3), which results in alterations in 
calcium and potassium concentrations that lead to enhanced excitability (Raza et al., 2004; 
Smolders et al., 1997, Smolders et al., 1996).  
The increased excitability in the hippocampus resulted in the decreased activity of ATPases 
that were unable to repolarize the membrane or promote calcium extrusion (Fernandes et 
al., 1996; Funke et al., 1998). High intracellular calcium can promote glutamate release, 
which by activating glutamate receptors allows the influx of additional calcium to induce 
SE, excitotoxicity and cell death (Smolders et al., 1997; Fernandes et al., 1996). In these 
experimental models, the recurrent spontaneous seizures occurred after a latent period, 
which is reminiscent of the human TLE (Mello et al., 1993). Inflammatory mediators have 
been described in the hippocampus of rats treated with pilocarpine, and molecules, such as 
kinins and prostaglandins, and also participate in the pathophysiology of TLE (Naffah-
Mazzacoratti et al., 1995; Argañaraz et al., 2003; Perosa et al., 2007).  
Kindling is an animal model of TLE where increasingly stronger seizures are induced by 
electrically stimulating brain areas (Goddard et al., 1969). Repeated seizures induce 
progressive cellular alterations, not only in the hippocampus, but also in the amygdala and 
the entorhinal cortex (Cavazos et al., 1994). Furthermore, studies have demonstrated that the 
neuronal loss is accompanied by aberrant mossy fiber axonal growth of the dentate granule 
cells in the hippocampus (Cavazos et al., 1991). 
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5. Molecular changes in epileptogenesis 
Significant cell death and reorganization occurs in the CA1 region, and studies have shown 
an intense synaptic reorganization of calbindin and parvalbumin-positive neurons, which 
are presumably GABAergic neurons, that results in the inhibition of inhibitory neurons 
leading to abnormal synchrony and seizure activity (Wittner et al., 2002). This suggests that 
hyperexcitability is not due to the loss of Ǆ-aminobutyric acid (GABA) but involves other 
mechanisms that are related to increased excitatory neurotransmission. In addition, there is 
evidence that mossy cells in the hilus and pyramidal neurons in the CA3 region show 
increased expression of GluR1 that promotes the excitation of granule cells (Eid et al., 2002). 
To date, studies have focused on the increased astrogliosis in this region, which could also 
contribute to the hyperexcitability. There is evidence that astrocytes contribute to the high 
levels of glutamate in hippocampal areas where neurons are sparse (De Lanerolle & Lee, 
2005). Some changes in astrocytes, such as high sodium channels expression, reduced 
inward rectifying potassium channels, elevated expression of GluR1 and downregulation of 
glutamine synthetase, an enzyme responsible for the conversion of glutamate to glutamine, 
represent potential mechanisms by which astrocytes can release glutamate (O'Connor et al., 
1998; Schroder et al., 2000; Eid et al., 2004, van der Hel et al., 2005).  
Astrocytes can modulate the inflammatory reactions through the expression of the 
transcription factor nuclear factor kB (NF-kB) and activation of prostaglandin E2 (PGE2) in 
response to interleukin-1ǃ (IL-1ǃ) (Dong & Benveniste, 2001). PGE2 increases calcium levels 
within astrocytes and contributes to glutamate release (Bezzi et al., 1998).  
In addition to IL-1ǃ, astrocytes can also produce other immunological agents, such as 
interleukins (IL-1, IL10 and IL-6), interferon-alpha and beta (IFN-ǂ and ǃ), tumor necrosis 
factor-alpha (TNF-ǂ) and transforming growth factor-beta (TGF-ǃ) (Dong & Benveniste, 
2001; John et al., 2005). Studies have shown that IL-1ǃ is upregulated in the sclerotic 
hippocampus from patients with TLE and can exacerbate seizures through glutamate 
release (John et al., 2005). The genes regulated by IL-1ǃ are upregulated in sclerotic 
hippocampi from TLE patients (John et al., 2005). 
Growing evidence indicates that purines are widely involved in the molecular mechanisms 
underlying the various functions of astrocytes, either by modulating intracellular molecules 
involved in energy metabolism and nucleic acid synthesis or by activating a variety of 
membrane receptors (Neary et al., 1996; Abbrachio & Burnstock, 1998). By activating P2 
receptors, purines can also modulate calcium influx, and there is substantial evidence that 
cellular cascades initiated by calcium influx and perturbed intracellular calcium homeostasis 
are involved in the status epilepticus-induced excitotoxic cell death. Other studies have 
indicated that large amounts of ATP released from dying cells after the insult might induce 
reactive astrogliosis, microglia proliferation and act as a powerful chemoattractant at the site 
of injury (Davalos et al., 2005). Both astrocytes and activated microglia are able to induce the 
release of cytokines, such as IL-1ǃ, TNF-ǂ, and IL-6, which could influence the 
neuroinflammatory processes during neurodegeneration (Sanz & Di Virgilio, 2000). The 
activation of microglial P2X7 receptors by ATP induces TNF-ǂ release, and this effect is 
regulated by extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein 
(MAP) kinase (Suzuki et al., 2004). 
It is not known whether microglia protect or damage neurons or whether TNF is beneficial 
or toxic. However, recent studies have demonstrated that P2X7 receptors were able to 
modulate the immune response of glial cells, and the expression of P2X7 receptors was 
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increased in the rat hippocampus following pilocarpine-induced SE (Dona et al., 2009; 
Fernandes et al., 2010). Several authors have reported that the neuroinflammation is an 
injury-induced glial activation that can contribute to the pathology of epilepsy (Naffah-
Mazzacoratti et al., 1995; Rappold et al., 2006; Vezzani & Granata, 2005). 
6. Cell death secondary to seizures  
The mechanism by which seizures cause neuronal death is understood based on studies that 
examined glutamatergic neurotransmission. The glutamatergic neurotransmission induced 
by excitotoxicity leads to the over-activation of glutamate receptors, which causes an 
excessive influx of Na+ and Ca2+ that induces osmolytic stress, cell swelling/rupturing, free 
radical production, which damages DNA, and protease activation leading to the proteolysis 
of cell and organelle membranes. This ultimately culminates with cell necrosis (Fujikawa, 
2005, 2006). The glutamate-mediated excitotoxicity and necrosis are primary contributing 
factors, but seizures also activate programmed cell death pathways, such as apoptosis 
(Henshall 2007, 2008).  
7. Apoptosis  
Apoptosis is the physiological process of programmed cell death (Strasser et al., 2000). 
Apoptotic signals through a highly ordered molecular cascade that is energy-dependent and 
may involve new gene transcription. Several studies have identified key genes in the 
nematode worm, Caenorhabditis elegans, that promoted (ced-3, ced-4) or inhibited (ced-9) 
apoptosis (Ellis and Horvitz, 1986; Hengartner et al., 1992). Further, the mammalian 
homologues of these genes allowed for the characterization of two classes of proteins 
involved in apoptosis: caspases and Bcl-2 (Hengartner and Horvitz, 1994; Yuan et al., 1993).  
8. Caspases and Bcl-2 
Caspases are aspartate-specific cysteine proteases present in cells as zymogens. A 
proteolytic cleavage is required for the enzymes to become active. In mammals, fourteen 
types of caspases have been identified and were divided into the inflammatory/cytokine-
processing caspases that include -1, -4, -5, -11, and -12. The apoptosis-regulatory caspases 
were divided into initiators of apoptosis that include -8, -9, and -10, and the apoptotic 
executioners are caspases -3, -6, and -7 (Thornberry and Lazebnik, 1998; Henshall & Simon, 
2005). The activation of cell death signaling is initiated by a caspase, which will then activate 
specific executioner caspases. The executioner caspases will cleave key structural and 
functional proteins within the cell, such as actin and the inhibitor of caspase-activated 
DNase (ICAD), as well as providing feedback loops for further processing of caspases 
(Mashima et al., 1997; Sakahira et al., 1998; Thornberry and Lazebnik, 1998; Henshall and 
Simon, 2005). 
The Bcl-2 gene family is comprised of more than 20 different members that regulate 
apoptosis positively, pro-apoptotic, or negatively, anti-apoptotic, primarily by affecting the 
mitochondria (Henshall and Simon, 2005; Kroemer et al., 2007). Many efforts have been 
made to elucidate the role of Bcl-2 proteins in apoptosis (Henshall & Simon, 2005; Kim et al., 
2006). The pro-apoptotic Bcl2 family protein, Bax, becomes active by binding to tBid and 
can trigger the formation of pores in the mitochondrial membrane, which allows the 
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release of the apoptogenic factor, cytochrome c. The Bcl-2 pro-apoptotic proteins, Bim and 
Puma, neutralize the anti-apoptotic protein Bcl2. The proteins Bcl-2 and Bcl-xl confer 
protection by promoting oligomerization with pro-apoptotic members, by maintaining the 
integrity of the mitochondria, by mobilizing calcium and by acting as an antioxidant 
(Henshall & Simon, 2005). 
The high level of intracellular calcium (Ca2+) that results from the activation of glutamate 
can trigger mitochondrial dysfunction directly or activate calcium phosphatases (e.g., PP2B 
and calcineurin) or regulatory molecules responsible for the release of Bad from the anti-
apoptotic protein, 14-3-3 (for details see Henshall & Simon, 2005). The transcription factor, 
Fox-O, is involved as a second regulatory step, is activated by dephosphorylation and 
upregulates Bim, whereas p53 upregulates Puma. These BH3-only proteins may promote 
Bax/Bak by inactivating the anti-apoptotic Bcl-2, Bcl-xl, Bcl-w or by directly activating 
Bax/Bak. Cytochrome c is released from Apaf-1, which then triggers caspase-9 activation, 
blocks various heat shock protein (HSP) activity and the X-linked inhibitor of apoptosis 
protein (XIAP). The extrinsic and intrinsic pathways converge on the activation of the 
executioner caspases, -3 and -7 that can then cleave key substrates (e.g., ICAD). 
The endoplasmic reticulum (ER) is an organelle that acts as a key trigger in the induction of 
the intrinsic pathway of apoptosis (Xu et al., 2005). Protein misfolding that arises from an 
increased intracellular calcium level can act as a potential ER stressor. Under persistent 
stress, apoptosis is triggered by a mitochondrial-mediated pathway (Smith & Deshmukh, 
2007), and this process requires Bax for the initiation of the pathway and Apaf-1 for cell 
death execution (Smith & Deshmukh, 2007).  
9. Intrinsic and extrinsic pathways of apoptosis 
Apoptosis can be initiated by two different routes known as extrinsic death receptor 
pathway, and intrinsic mitochondrial pathway (see Henshall and Simon, 2005).  
In the extrinsic pathway, a cell death-promoting stimulus activates an initiator caspase via a 
recruitment scaffold. Activation of the cell surface-expressed death receptors, such as the 
TNF superfamily (TNFR1; TNF receptor 1) or Fas, causes the death effector domains (DED) 
within the prodomain to bind to homologous regions on the death receptor (DR) adaptor 
proteins, such as Fas-associated death domain (FADD), which forms an intracellular 
complex known as the DISC (death-inducing signaling complex), leading to caspase-8 
activation (Henshall, 2005, Thornberry and Lazebnik, 1998).  
The caspase cascade is initiated by caspase-8 and culminates with the activation of 
executioner caspases, such as caspase-3, which cleave intracellular structural and survival 
proteins and activate enzymes responsible for DNA fragmentation (Henshall and Simon, 
2005, Thornberry and Lazebnik, 1998).  
The intrinsic pathway is triggered following the disruption of intracellular organelle 
homoeostasis or DNA damage (Verhagen et al., 2000). This pathway is characterized by 
mitochondrial dysfunction that causes the release of apoptogenic factors, such as 
cytochrome c, which activates Apaf-1 (apoptotic protease-activating factor 1) and caspase-9 
and is followed by downstream executioner caspase activation and cell death (Figure 3). 
Smac/DIABLO is released following mitochondrial damage and blocks active caspase 
inhibitors (Verhagen et al., 2000).  
The cross-talk between the two apoptotic pathways can occur through the cleavage of Bid 
by activated caspase-8. Cleavage of Bid leads to truncated Bid (tBid) formation, which 
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translocates into the mitochondria and induces the release of cytochrome c and 
Smac/DIABLO (Figure 3) (Madesh et al., 2002). 
10. Seizures activate apoptosis 
Several studies have indicated that seizures can activate the intrinsic and extrinsic apoptotic 
pathways in the brain (Henshall, 2007). The release of cytochrome c, Apaf-1, activated 
caspase-9 and -3 and subsequent DNA fragmentation in the rat hippocampus after a short 
SE duration indicate activation of the intrinsic pathway (Turski et al., 1983; Leite et al., 1990). 
Further, the intrinsic pathway can be activated by calcium. Pro-apoptotic Bcl-2 proteins 
(Bad, Bid and Bim) can be activated via calcium-dependent mechanisms, and each protein 
was found to be activated by seizures in vivo (Weiss et al., 1986; Mello et al., 1993). 
The importance of the Bcl-2 family in human epilepsy has been studied extensively. 
Elevated Bcl-w, reduced Bim and normal levels of Bcl-xl, Bax, Bad and Bid have been 
reported in the hippocampus obtained from patients with intractable seizures (Murphy et 
al., 2007; Shinoda et al., 2004, Yamamoto et al., 2006a). Serum analysis has also provided 
indirect evidence for the modulation of Bcl-2 in patients with epilepsy (El-Hodhod et al., 
2006). These Bcl-2 expression patterns may reflect the repertoire of genes that regulate cell 
death that may lower the vulnerability of the brain to further neuronal loss (El-Hodhod et 
al., 2006). Indeed, repeated electroshock seizures in rats and mice, a protocol used to evoke a 
damage-refractory state, adjust the balance of pro- and anti-apoptotic Bim and Bcl-w levels 
and demonstrate a similar pattern to those observed in patients (Murphy et al., 2007; 
Shinoda et al., 2004).  
The secondary role of the extrinsic pathway in cell death during seizures was demonstrated 
by the presence of caspase-8 cleavage in the early stages following the seizures (Henshall et 
al., 2001). The cleavage of a select group of caspases (-3, -7, -8 and -9) was detected in the 
hippocampus of rats after repeated electroshock seizures, indicating that the progression 
of apoptosis signaling may occur (Yamamoto et al., 2006b, Schindler et al., 2006, 
Yamamoto et al., 2006c). 
In addition, activated TNFR1 and DISC were detected in a seizure-damaged hippocampus 
from rats (Henshall et al., 2003; Shinoda et al., 2003), and patients with TLE (Yamamoto et 
al., 2006).  
Currently, it is not known whether TNF is beneficial or toxic to neurons. TNF may enhance 
injury induced by ischemia and trauma (Barone et al., 1997; Meistrel et al., 1997) as well as 
provide neuroprotection by inducing the expression of anti-apoptotic and antioxidative 
proteins (Yang et al., 2002). The dual effect of TNF is mediated by different TNF receptors, 
with the p55 TNFR1 mediating the neurotoxic effect and p75 TNF receptor 2 (TNFR2) 
eliciting the neuroprotection (Yang et al., 2002). By blocking protein synthesis, TNFR1 can 
trigger apoptosis and cause stress to the ER in the hippocampus of a patient during seizures 
(Yamamoto et al., 2006; Shinoda et al., 2003). These data suggest that glutamate 
excitotoxicity is not the only mechanism resulting in cell death after seizures. Efforts have 
been made to determine the temporal order of intrinsic and extrinsic pathway activation to 
clarify the relevance of these signaling pathways in neuronal death that is secondary to 
seizures.  
In summary, apoptosis signaling pathways contribute to the neurodegenerative mechanism 
elicited by seizures and may be involved in epileptogenesis. Several apoptotic regulatory 
proteins have homeostatic functions in the cells involved with seizure or epilepsy 
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susceptibility, such as Bcl-2 members, Bax and Bak, which regulate intracellular calcium at 
the ER membrane (White et al., 2005). In this vein, altered levels of Bcl-2 proteins in the TLE 
patient’s brain may influence a spectrum of intracellular responses, including excitability. It 
has been reported that caspases can have other functions in addition to apoptotic signaling. 
The importance of activated caspases in normal cells during development and signaling has 
recently been extended to the CNS where these proteases have been shown to contribute to 
axon guidance, synaptic plasticity and neuroprotection (McLaughlin, 2004; Lamkanfi et al., 
2007). Finally, efforts have been made to elucidate the physiological and pathological role of 
Bcl-2 proteins and caspases in the brain.  
11. Caspase activity in temporal lobe epilepsy 
Several reports have shown that seizures can occur after the activation of caspase-1 
(Eriksson et al., 1999), caspase-3 (Becker et al., 1999; Kondratyev and Gale 2000; Weise et al., 
2005), caspase-8 (Tan et al., 2002) or caspases-2 and -9 (Henshall et al., 2001).  
Henshall et al. (2001) and Li et al. (2006) reported that caspase-8 and -9 are activated in the 
hippocampus 40 min after focal SE was induced by kainic acid. The different location of 
caspase expression after SE suggests different functions in the brain. Weise et al. (2005) 
reported the expression of activated caspase-3 in hippocampal neurons after pilocarpine-
induced SE while other authors (Narkilahti et al., 2003; Ferrer et al., 2000) have detected 
active caspase-3 primarily in astrocytes and, to a lesser degree, in neurons. These data 
suggest that caspase-3 could exert an important role in the astrocytic death following SE and 
may have other unknown functions. 
Using biochemical and immunohistochemistry assays, we have demonstrated that 
inflammatory caspase-1 and the apoptotic executioner caspase-3 are activated in the 
hippocampus of rats at 90 min after the seizure onset and at 7 days after SE (latent period) 
(in preparation). Interestingly, the most intense caspase activity was observed in the latent 
period where the highest amount of neuronal death occurs. The neuronal damage is 
necessary to generate spontaneous seizures in this model (Turski et al., 1983).  
The activation of caspase-1 by SE induced by pilocarpine is involved in inflammatory 
mediator generation. Fantuzzi et al. (1999) demonstrated that caspase-1 is specifically 
required for processing pro-IL-1ǃ and pro-IL-18 to their active forms. IL-1ǃ can modulate 
the hyperexcitability by increasing glutamate release (Kamikawa et al., 1998), inhibiting 
glutamate reuptake by glial cells (Ye and Sontheimer, 1996) and increasing the calcium 
influx mediated by NMDAR through activation of Src family kinases (Viviani et al., 2003). 
There are a growing number of studies showing the role of inflammation in the injury 
process caused by seizures (Ravizza et al., 2006; Vezzani et al., 1999; 2000). Thus, caspase-1 
inhibition may be a promising anticonvulsant and neuroprotective therapy. 
12. Caspase inhibition as neuroprotective strategy in temporal lobe epilepsy 
Because caspases are differentially activated during epileptogenesis as demonstrated by 
Gorter et al. (2007) using microarray assays, caspase selective inhibitors are considered 
potential targets for novel neuroprotective and anticonvulsant agents for epilepsy 
(Kondratyev and Gale, 2000; Henshall et al., 2001; Ravizza et al., 2006). Inhibition of caspase-
1 reduced seizures in rats, whereas the deletion of the caspase-1 gene delayed acute seizure 
onset (Ravizza et al., 2006). Inhibition of caspase-3 and -9 provides neuroprotection after SE 
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was induced by kainate (Henshall et al., 2001), and the inhibition of caspase-8 may attenuate 
neuronal death by decreasing cleaved Bid, caspase-9, and the release of cytochrome c from 
mitochondria (Li et al., 2006).  
The caspase inhibition was also used as a neuroprotective strategy against injury caused by 
SE induced by pilocarpine (Persike et al., 2008).  
Several studies determined that tellurium compounds, as the non-toxic AS-101, ammonium 
trichloro(dioxoethylene-O,O′) tellurate, exert anti-apoptotic, anti-inflammatory, and 
immunomodulatory effects (Okun et al., 2007a; Sredni et al., 2007). These effects are 
primarily caused by the unique tellurium-thiol chemistry, which enables the interaction 
between the tellurium compound with the reactive cysteine residues of the inflammatory 
and apoptotic caspases leading to caspase inhibition (Albeck et al., 1998; Okun et al., 2007b). 
AS-101 not only interacts with catalytic thiols from cysteine proteases but also interacts with 
non-catalytic thiols (Okun et al., 2007b). It has been demonstrated that AS-101 can 
upregulate the anti-apoptotic proteins Bcl-2, p21Ras, PI3 kinase and the glial cell line 
derived neurotrophic factor (GDNF), and AS-101 can inhibit IL-1ǃ and caspase-1 and -3 
(Makarovsky et al., 2003; Okun et al., 2006a,b; Sredni et al., 2007). AS-101 is currently being 
tested in Phase II clinical trials in cancer patients (Sredni et al., 1995, 1996, Frei et al., 2008) 
and was recently suggested as a promising agent for treatment of Parkinson's disease 
(Sredni et al., 2007). 
A compound of tellurium(IV), the organotelluroxetane RF-07 (see Figure 2), is an analogue 
of AS-101 (Persike et al., 2008). The administration of RF-07 prior to pilocarpine significantly 
blocked the behavioral and electrographic symptoms of SE in rats (Figure 3). To evaluate if 
this activity could be related to caspase inhibition, RF-07 was used in an “in vitro” assay to 
test recombinant caspases -3 and -8. RF-07 showed a potent inhibitory effect on both caspase 
-3 and -8 (Persike et al., 2008). The RF-07 was also tested in hippocampal homogenates from 
rats euthanized 90 min after pilocarpine-induced SE. RF-07 was the most potent inhibitor of 
caspase-like activity compared with commercial caspase inhibitors (Persike et al., 2008). 
Based on the results of this study, RF-07 inhibits not only caspases but other proteases that 
were activated during seizures, such as cathepsins, matrix metalloproteinases and 
plasminogen activators (see Figure 4). 
 
 
Fig. 2. The molecular structure of the neuroprotector tellurium(IV) compound, (4-{2-Chloro-
3-[chloromethylidene]-1-oxa-2l4-telluraspiro[3.5]non-2-yl}phenyl Methyl Ether). 
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Taken together, these data show that RF-07 represents a promising anti-epileptic and/or 
agent for epilepsy. Further investigations are ongoing to elucidate the mechanisms by which 
RF-07 inhibits pilocarpine-induced seizures. Studies using proteomic analysis may help to 
clarify these mechanisms. 
 
 
 
 
 
 
Fig. 3. Electroencephalographic recording showing the blockade of the brain high 
amplitude and frequency discharges (HAFD) following RF-07 injected prior to pilocarpine 
in rats. (A) N-methyl-scopolamine did not change the control recordings. N-methyl-
scopolamine was used to prevent the peripheral effects of pilocarpine. The electrographic 
seizure started 10 min after pilocarpine administration and was highly synchronized in 
the hippocampus and cortex. (B) The rats were pre-treated systemically with RF-07 15 min 
prior to pilocarpine. As shown, rats did not develop seizures, which exhibited 
electrographic activity in the hippocampus and cortex similar to the pre-pilocarpine 
pattern (Persike et al., 2008). 
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Fig. 4. A hypothetical diagram showing the signaling pathways modulated by RF-07. As 
previously described for AS-101, the RF-07 can bind to the cysteine residues of several 
proteins, such as Ras, cathepsins and caspases-1, -3 and -8. By binding to Ras, RF-07 
increased the enzymatic activity, but upon binding to caspases, inhibited its activity. Ras 
activates ERKs, which then induces the expression of Bcl-2 to protect neurons from 
oxidative stress and mitochondrial disruption. The inhibition of caspases -1, -3 and -8 can 
prevent apoptosis and reduce the production of the pro-inflammatory cytokine IL-1β. In 
parallel, RF-07 could inhibit IL-10 production in addition to an increase in the ratio of 
GSH/GSSG. This inhibition would result in GDNF/IL-6 upregulation. By inhibiting 
cathepsin, RF-07 reduced the degradation of extracellular matrix components (Based on 
Sredni et al., 2007; Cunha et al., 2005 and Gorter et al., 2007).  
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13. Conclusion 
Temporal lobe epilepsy is a progressive epileptic syndrome in which most of patients 
exhibit hippocampal sclerosis characterized by pyramidal cell degeneration, astrogliosis and 
aberrant mossy fiber sprouting in the inner molecular layer of the dentate gyrus. We have 
demonstrated that the caspase-mediated inflammatory process has been reported as a 
possible mechanism involved with the pathogenesis of TLE, and caspase inhibitors could be 
a promising therapeutic strategy. The knowledge about the physiological role of caspases in 
the CNS could improve our understanding about the balance between mediators of survival 
and cell death in the epileptogenesis.  
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